GPS LR Summary Guide

Genomic Prostate Score
for Localized Prostate Cancer

This guide is intended to be a concise summary of key information from the Genomic Prostate Score (GPS) report for the provider. Please continue to the following pages for full report.

Lastname, Firstname DOB: MM/DD/YYYY

GPS 10

At Decreased Risk

Low Likelihood of Adverse Pathology (22%)
≥Gleason 4+3, and/or non-organ confined ≥pT3a disease

Consider Active Surveillance[1]

- High-Grade Disease (Gleason ≥ 4+3): 11%
- Non-Organ Confined Disease (≥pT3a): 12%
- Metastasis Within 10 Years After Radical Prostatectomy: 4%
- Prostate Cancer Death Within 10 Years After Radical Prostatectomy: <1%
- Data from GPS's pivotal clinical validation studies suggest this patient has a moderate likelihood of adverse pathology, compared to other patients in the clinical validation studies. Patients in this group had an average GPS result of 28.[2,3]
- Continue to take other risk factors into account such as clinical, pathological, and family history.
- Clinical and pathological risk factors are not used to determine a numerical GPS Result.



Patient clinical and pathological features: NCCN Favorable Intermediate Risk[1]

Gleason	# of Positive Cores	Max % Tumor Involvement	Stage	PSA (ng/mL)	PSAD (ng/mL/cc)
3+4	1	≤50%	T1c	7.2	<0.15

Questions? Email gps@mdxhealth.com

References: 1. NCCN Clinical Practice Guidelines in Oncology. Prostate Cancer. Version 1.2024; 2. Klein EA, et al. Eur Urol. 2014; 3. Cullen J et al. Eur Urol. 2015.

Learn more about GPS:

CLIA# 05D2033858; CAP# 8015399.

mdxhealth

Mdxhealth • 15279 Alton Parkway, Suite 100, Irvine, CA 92618 • P: 866.259.5644 • F: 949.788.0014 • E: cs@mdxhealth.com • www.mdxhealth.com

GPS Report

For NCCN Very Low, Low, and Favorable Intermediate Risk Groups

Genomic Prostate Score®
(Formerly Oncotype DX GPS)

LASTNAME, FIRSTNAME MI.

Date of Birth: **DD-Mmm-YYYY** mdx #: **A123456** Physician:

Report Date: **01-Dec-2025** Account:

Submitted NCCN Risk Group[a],[1]: Favorable Intermediate

Physician-Provided Information[b]:

Gleason Score: **3+4**

PSA (ng/mL): **7.2**

Clinical Stage: **T1c**

Max. % of tumor involvement in any core: **≤ 50%**

Prostate Volume (cc): **51.00**

PSA Density (ng/mL/cc): **0.14**

Number of Cores Positive: **1**

Number of Cores Collected: **12**

Patient's GPS Result is 10



The graph above shows the range of GPS results with estimates of likelihood of adverse pathology for NCCN Favorable Intermediate risk. [2, 3]

Likelihood of Adverse Pathology at Radical Prostatectomy [d]



Clinical Interpretation[e]

- This patient's likelihood of adverse pathology *(Gleason Score ≥4+3 and/or ≥pT3a)* at radical prostatectomy is **22%** *(95% CI: 15% - 31%)* based on the combined GPS result and NCCN risk group.
- Data from the clinical validation studies suggest this patient has a **low likelihood** of adverse pathology, compared to other patients in the clinical validation studies. [2,3]
- In our clinical validation studies, 43% of patients with NCCN Favorable Intermediate risk prostate cancer had adverse pathology at radical prostatectomy. [2,3]

(a) Calculated or reported from physician-provided clinical information. (b) N/A (not available) indicates data has not been provided to Genomic Health. (c) Distribution curve for illustrative purposes only. (d) Based on GPS result & submitted NCCN risk group. (e) All Patients in the clinical validation studies have been treated with radical prostatectomy.

GPS Report

For NCCN Very Low, Low, and Favorable Intermediate Risk Groups

Genomic Prostate Score®
(Formerly Oncotype DX GPS)

LASTNAME, FIRSTNAME MI.

Date of Birth: **DD-Mmm-YYYY** mdx #: **A123456** Physician:

Report Date: **01-Dec-2025** Account:

Medical Record/Patient #: **1234567-01** Specimen Type/ID: **Slides/SP-16_0123456**

Date of Collection: **10-Apr-2023**

Specimen Received: **12-Apr-2023**

ADVERSE OUTCOME	LIKELIHOOD OF ADVERSE OUTCOME	CLINICAL INTERPRETATION
High-Grade Disease (Gleason ≥ 4+3)		The risk estimates provided are based on the patient's GPS result and submitted NCCN risk group. In our clinical validation studies, all patients received radical prostatectomy. [2,3]
Non-Organ Confined Disease (pT3+)		

ADVERSE OUTCOME	LIKELIHOOD OF ADVERSE OUTCOME	CLINICAL INTERPRETATION
Metastasis Within 10 Years After Radical Prostatectomy (f)		In our clinical validation studies, **no patient with a GPS result <20 had metastasis or died** from prostate cancer within 10 years post radical prostatectomy.[4]
Prostate Cancer Death Within 10 Years After Radical Prostatectomy		

The Oncotype DX Genomics Prostate Score (GPS) test is a continuous scale (0-100) that quantifies expression of 17 genes in tumor tissue as assessed by RT-PCR. The GPS Test has been validated in three prospectively designed studies (N=1056) of biopsy tissue from patents with localized prostate cancer. [2,3,4]

(f) In the clinical validation study, metastasis was determined by imaging or biopsy.

References: 1. From the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer Version 1.2024. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. To view the most recent and complete version of the guideline, go online to NCCN.org. 2. Klein E et al. Eur Urol. 2014. 3. Cullen J et al. Eur Urol. 2015. 4. Van Den Eeden S et al. Eur Urol. 2017.

General information about Genomic Prostate Score can be found at www.mdxhealth.com. If you have any questions regarding this report, please contact mdxhealth Client Services at 866.259.5644 or cs@mdxhealth.com.

Ruben Gamez, MD, Laboratory Director

CAP ACCREDITED
COLLEGE of AMERICAN PATHOLOGISTS

P: 866.259.5644 | F: 949.788.0014
E: cs@mdxhealth.com | www.mdxhealth.com

Test performed at:
Mdxhealth, Inc. 15279 Alton Parkway, Suite 100
Irvine, CA 92618 USA